Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Sintilimab in 2nd-line Advanced Gastric Cancer
NCT05928897Phase 2Unknown
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of disitamab vedotin in gastric cancer (GC), sponsored by Xiangya Hospital, Central South University. Status: unknown.
02
Drugs
disitamab vedotin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05928897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05928897.